Results 211 to 220 of about 47,580 (341)

AK112 (PD-1/VEGF-a bispecific antibody) combined with chemotherapy in locally advanced pancreatic cancer: a case report. [PDF]

Front Oncol
Yan J, Dong H, Wu C, Gu H, Qi Z, Chen T, Hu B, Zhou H, Long J.   +8 more
europepmc   +1 more source

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT G protein‐coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody‐based therapies. This review offers an overview of the therapeutic GPCR‐antibody target landscape and examines the diversity ...
Catherine J. Hutchings, Serbülent Ünsal, Mathieu Rappas, Matthew Barnes, Maria Waldhoer, Ben Holland, Martin Culka   +6 more
wiley   +1 more source

A Bispecific Antibody Blocking Both TSLP and IL-4Rα for the Treatment of Allergic Inflammatory Diseases. [PDF]

Cells
Yu M, Chen P, Jin Y, Huang S, Jiang H, Zhou F, Chiu ML, Zhang D.   +7 more
europepmc   +1 more source

Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT This study demonstrates the application of a model based meta analysis (MBMA) framework to characterize the safety and efficacy profiles of therapies in relapsed and refractory multiple myeloma (RRMM). Published clinical trial data were analyzed to evaluate the incidence of Grade ≥ 3 neutropenia and overall response rate (ORR), providing a ...
Zeel Shah, Clifton M. Anderson, Kevin D. McCormick, Celeste Vallejo, William Duncan, Chuanpu Hu, Jian Zhou, Alexander V. Ratushny, Anna G. Kondic   +8 more
wiley   +1 more source

Removal of Aggregates During Bispecific Antibody Purification Using Hydrophobic Interaction Chromatography. [PDF]

Membranes (Basel)
Zhao P, Qi Y, Gao K.
europepmc   +1 more source

Bispecific Antibody MDX447 [PDF]

, 2020
openaire   +1 more source

A Generalized Minimal PBPK‐PD Model of Bispecific Antibodies: Case Studies and Applications in Drug Development

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Bispecific antibodies (bsAbs), for which each arm binds a distinct molecular target, are developed to engage soluble and cell surface targets in different therapeutic indications. Three key examples of mechanisms of action (MoA) for bsAbs are (1) immune cell engagers that foster immune cell interactions with target cells, (2) bispecifics that ...
Phillip Spinosa, Louis Joslyn, Saroja Ramanujan, Kapil Gadkar, Iraj Hosseini   +4 more
wiley   +1 more source

Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma. [PDF]

Biomolecules
Seo H, Go D, Jung SY, Han S, Nguyen VQ, Kwak M, Um W.   +6 more
europepmc   +1 more source

NLRP3 Inflammasome Inhibition by the Novel Bispecific Antibody InflamAb Attenuates Atherosclerosis in Apolipoprotein E–Deficient Mice

Lucie Delfos, Marie A.C. Depuydt, Melody Chemaly, Sophie Coyle, Frank H. Schaftenaar, Peter J. van Santbrink, Pier Pieterszoon Lindenbergh, Mireia N. A. Bernabé Kleijn, C. Costello, Christopher Power, Rebecca C. Coll, Aaron Peace, Meredith Gregory‐Ksander, Amanda C. Foks, Johan Kuiper, Victoria McGilligan, Ilze Bot   +16 more
openalex   +1 more source

Quantitative Prediction of Human Pharmacokinetics for Fc‐Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Fc‐engineered antibodies (mAbs) enhancing FcRn binding have rapidly expanded in drug discovery and development. Although an approach exists for predicting the pharmacokinetics of Fc‐engineered mAbs after intravenous injections in humans, no methodology has been established for predicting pharmacokinetics after subcutaneous injections.
Kenta Haraya, Taichi Kuramochi
wiley   +1 more source